About Adicet Bio Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.adicetbio.com/
Frequently Asked Questions
What is the 52-week range for ACET?
The 52-week high is $17.44 and the 52-week low is $6.01.
What is the P/E ratio for ACET?
The P/E ratio data is currently unavailable.
What is the dividend yield for ACET?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -74.90%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -93.15%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.51.
Analyst Recommendation Trends
Wall Street analyst consensus for ACET over the last few months:
Latest ACET News
Adicet Bio’s Prula-Cel Delivers 54% Lupus Remission Rate at 12 Months
Adicet Bio (NASDAQ:ACET) reported positive clinical data for prula-cel, its investigational allogeneic gamma delta CAR-T cell therapy, in patients with systemic lupus erythematosus, or SLE, including patients with lupus nephritis. The company said that, among evaluable lupus nephritis patients, 50%
Adicet Bio, Inc. (ACET) Discusses Positive Prula-cel Data and Plans for Pivotal Study in Lupus Nephritis - Slideshow
2026-09-30. The following slide deck was published by Adicet Bio, Inc.
Wedbush Maintains Outperform on Adicet Bio, Raises Price Target to $28
Wedbush analyst Robert Driscoll maintains Adicet Bio (NASDAQ:ACET) with a Outperform and raises the price target from $25 to $28.
Adicet Bio Reports Positive Prula-cel Phase 1 Lupus Data as Pivotal Study Plans Advance
Adicet Bio (NASDAQ:ACET) reported 12-month DORIS remission in 54% of evaluable systemic lupus erythematosus patients and complete renal response in 50% of evaluable lupus nephritis patients, supporting plans to begin pivotal study start-up activities in the fourth quarter of 2026. Key Investor TakeawaysAdicet Bio (NASDAQ:ACET) reported positive prula-cel Phase 1 lupus data from 22 efficacy-evaluable patients, including 16 with lupus nephritis and six with extra-renal SLE.
Let's uncover which stocks are experiencing notable gaps during today's session.
The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Adicet Bio, Inc. (ACET) Discusses Positive Prula-cel Data and Plans for Pivotal Study in Lupus Nephritis Transcript
Adicet Bio, Inc. (ACET) Discusses Positive Prula-cel Data and Plans for Pivotal Study in Lupus Nephritis September 28, 2026 8:00 AM EDTCompany...
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Kodiak Sciences (NASDAQ:KOD) shares moved upwards by 172.3% to $88.08 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. Accuray (NASDAQ:ARAY) shares moved
Is Tenet Healthcare (THC) Outperforming Other Medical Stocks This Year?
Here is how Tenet Healthcare (THC) and Adicet Bio, Inc. (ACET) have performed compared to their sector so far this year.
Adicet Bio Reports Phase 1 Prula-cel Data in Lupus Patients
Adicet Bio, Inc. (NASDAQ:ACET) reported Phase 1 clinical data for prulacabtagene leucel, or prula-cel, its investigational allogeneic gamma delta CAR-T cell therapy, in patients with systemic lupus erythematosus with or without lupus nephritis.
Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
REDWOOD CITY, Calif., September 28, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced safety and efficacy data from the Phase 1 study evaluating prulacabtagene leucel (prula-cel) as a potential treatment for patients with systemic lupus erythematosus (SLE) with or without lupus nephritis (LN). The
HC Wainwright & Co. Maintains Buy on Adicet Bio, Raises Price Target to $34
HC Wainwright & Co. analyst Robert Burns maintains Adicet Bio (NASDAQ:ACET) with a Buy and raises the price target from $27 to $34.
Adicet Bio Announces Safety And Efficacy Data From Phase 1 Study Evaluating Prulacabtagene Leucel In Patients With Systemic Lupus Erythematosus With Or Without Lupus Nephritis; Prula-Cel Generally Well Tolerated With No CRS Greater Than Grade 2 And No IEC-HS Or ICANS
-At 12-months, 54% of evaluable patients achieved DORIS remission and 50% of patients achieved CRR--All patients discontinued immunosuppressants –- All but one patient tapered background steroids to ≤5 mg prednisone
Why Webuy Global Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Webuy Global shares jumped 15% premarket after H1 revenue nearly doubled to $14.31M and net loss narrowed; Game Your Game led gainers, Masonglory fell.
Curious about the stocks that are showing activity after the closing bell on Friday?
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
REDWOOD CITY, Calif., September 25, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that the Company will report clinical data from the Phase 1 study evaluating prulacabtagene leucel (prula-cel) as a potential treatment for patients with systemic lupus erythematosus with or without lupus nephriti
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Onconetix (NASDAQ:ONCO) stock increased by 10.3% to $1.14 during Friday's after-market session. The market value of their outstanding shares is at $3.9 million. Bullfrog AI Hldgs (NASDAQ:BFRG) shares moved
Adicet Bio To Report Clinical Data From Phase 1 Study Evaluating Prulacabtagene Leucel As Potential Treatment For Patients With Systemic Lupus Erythematosus With Or Without Lupus Nephritis On September 28
Adicet Bio, Inc. (NASDAQ:ACET), a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid
HC Wainwright & Co. Reiterates Buy on Adicet Bio, Maintains $27 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Adicet Bio (NASDAQ:ACET) with a Buy and maintains $27 price target.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-05 | Klickstein Lloyd | +18,300 | - | - |
| 2026-06-21 | Peng Katie | +4,200 | - | - |
| 2026-06-21 | Klickstein Lloyd | +4,200 | - | - |
| 2026-06-21 | Sinclair Andrew | +4,200 | - | - |
| 2026-06-21 | Grissinger Michael | +4,200 | - | - |
| 2026-06-21 | Chodakewitz Jeffrey | +4,200 | - | - |
| 2026-06-21 | DUBIN STEVE | +4,200 | - | - |
| 2026-06-19 | Aftab Blake | +55,000 | - | - |
| 2026-06-19 | Schor Chen | +55,000 | - | - |
| 2026-04-27 | RA Capital Healthcare Fund LP | +250,000 | - | - |
| 2026-04-27 | RA Capital Healthcare Fund LP | -250,000 | - | - |
| 2026-04-08 | ORBIMED ADVISORS LLC | -40,416 | $6.52 | $263,512 |
| 2026-04-08 | ORBIMED ADVISORS LLC | -32,523 | $6.29 | $204,570 |
| 2026-04-07 | ORBIMED ADVISORS LLC | -2,400 | $6.38 | $15,312 |
| 2026-04-07 | ORBIMED ADVISORS LLC | -29,319 | $6.53 | $191,453 |
| 2026-03-25 | Maltzman Julia D. | +72,555 | - | - |
| 2026-03-25 | Aftab Blake | +72,555 | - | - |
| 2026-03-25 | Healey Don | +43,361 | - | - |
| 2026-03-25 | Harvey Brian Nicholas | +43,361 | - | - |
| 2026-03-25 | Schor Chen | +468,555 | - | - |
| 2026-02-20 | RA Capital Healthcare Fund LP | +74,751 | $7.27 | $543,440 |
| 2026-02-19 | RA Capital Healthcare Fund LP | +74,268 | $7.21 | $535,472 |
| 2026-02-18 | RA Capital Healthcare Fund LP | +74,577 | $7.04 | $525,022 |
| 2026-01-24 | Aftab Blake | -535 | $8.44 | $4,515 |
| 2026-01-24 | Healey Don | -535 | $8.44 | $4,515 |
| 2026-01-24 | Harvey Brian Nicholas | -546 | $8.44 | $4,608 |
| 2026-01-24 | Schor Chen | -1,755 | $8.44 | $14,812 |
| 2025-10-08 | ORBIMED ADVISORS LLC | +3,500,000 | $1 | $3,500,000 |
| 2025-10-08 | ORBIMED ADVISORS LLC | +1,500,000 | $1 | $1,500,000 |